Miami, FL (July 10, 2020) – Biorasi, a leading global full-service contract research organization (CRO), has met the First Patient, First Visit milestone for a dermatology trial across multiple sites during the COVID-19 pandemic. The trial, focused on treatment for pruritus, spans about 50 clinical sites throughout the United States.
“Ninety-three percent of our ongoing clinical trials are hitting their important milestones,” said Chris O’Brien, CEO of Biorasi. “It is a testament to our Operations Team’s dedication to site communication and proactive solutions that keeps our trials running on time.”
Understanding Decentralized Solutions
Biorasi was able to meet the First Patient, First Visit milestone for the dermatology trial by working closely with the identified sites during quarantine, ensuring patient and clinical staff safety protocols were ready for upcoming site activation. Additionally, by leveraging decentralized solutions – ranging from remote SSV and SIV to the use eSourcing technologies – Biorasi will be able to streamline upcoming aspects of the trial and continue to remain on schedule.
“As clinical trial sponsors become more familiar with the opportunities and limitations made real by COVID-19, more and more studies will begin to reactivate and move forward,” notes O’Brien. “As a leader in the CRO industry, Biorasi relies on its three pillars of success – the right team, the right technology, and the right processes – to engage with our partners and keep trials on track over the long term.”
Biorasi is a customer-focused, full-service, contract research organization (CRO) that optimizes the design and delivery of clinical trials for its sponsors, powered by our proprietary TALOS™ project management system. Pharmaceutical companies around the globe rely on Biorasi to consistently deliver success in clinical trial programs for rare and orphan disease and other hard to recruit patient populations such as precision medicine, as well as successful clinical trial rescue. Biorasi’s expertise includes a wide range of molecule types, therapeutic areas, and regulatory pathways. Biorasi is a leader in neurology, nephrology, dermatology, oncology, and the emerging digital therapeutics market.
Established in 2002, Biorasi is headquartered in Aventura, FL, with office-based teams around the globe. From its regional presences, Biorasi is able to directly support studies in the Americas, Europe, and APAC. The company has received the coveted CRO Leadership Award from Life Science Leader magazine and has been placed on the INC 500 list of fastest-growing companies in America.
To learn more about Biorasi’s mission and vision, including our full spectrum of decentralized clinical trials, explore our solutions on our website or contact us at email@example.com or (786) 388-0700.